ReviewFrontiers in immunology2026
Liquid biopsy in cancer drug resistance: real-time monitoring, mechanistic insights, and translational applications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy provides a non-invasive approach for cancer detection. It examines tumor-associated components in blood and other body fluids, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, including exosomes). This technology is transforming cancer diagnosis, prognosis, and therapy monitoring. This review summarizes recent advancements in liquid biopsy technologies, particularly focusing on circulating tumor components such as ctDNA, CTCs, and EVs. This review emphasizes the role of liquid biopsy in the early detection of drug resistance and therapeutic response monitoring. A primary emphasis is on how liquid biopsy detects various forms of drug resistance. It evaluates treatment efficacy, monitors alterations in tumor genomics over time, and assists in customizing therapy for people. We also discuss the integration of liquid biopsy with innovative technologies such as artificial intelligence and big data. The objective is to provide practical guidance for the future development of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.